Zentalis Pharmaceuticals Llc
$ 1.35
1.50%
31 Dec - close price
- Market Cap 97,539,000 USD
- Current Price $ 1.35
- High / Low $ 1.36 / 1.31
- Stock P/E N/A
- Book Value 3.50
- EPS -2.08
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.49 %
- 52 Week High 3.33
- 52 Week Low 1.01
About
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of innovative small molecule therapies for cancer treatment through precision medicine. The company boasts a robust pipeline targeting key pathways associated with tumor growth and resistance, addressing significant unmet medical needs in oncology. With its strategic focus on pioneering therapeutic solutions and a commitment to enhancing cancer care, Zentalis positions itself as a compelling investment opportunity for institutional investors seeking to leverage breakthroughs in cancer therapeutics.
Analyst Target Price
$5.31
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-06 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-08-09 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-09 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.37 | -0.37 | -0.67 | -0.6138 | -0.56 | -1.24 | 0.14 | -0.93 | -0.79 | -1.85 | -1.07 | -0.92 |
| Estimated EPS | -0.53 | -0.54 | -0.6069 | -0.6817 | -0.8708 | -0.84 | -0.77 | -0.92 | -0.91 | -1.04 | -1.02 | -1.06 |
| Surprise | 0.16 | 0.17 | -0.0631 | 0.0679 | 0.3108 | -0.4 | 0.91 | -0.01 | 0.12 | -0.81 | -0.05 | 0.14 |
| Surprise Percentage | 30.1887% | 31.4815% | -10.3971% | 9.9604% | 35.6913% | -47.619% | 118.1818% | -1.087% | 13.1868% | -77.8846% | -4.902% | 13.2075% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4796 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZNTL
2025-12-11 21:09:22
Oppenheimer has lowered its price target for Zentalis Pharmaceuticals (ZNTL) stock to $10, down from the previous $12. Despite the reduction, the firm decided to maintain its Outperform rating on the stock. This adjustment comes after a review of the company's financial outlook and potential market performance.
2025-11-10 22:09:44
Zentalis Pharmaceuticals has significantly reduced its third-quarter net loss to $26.7 million by aggressively cutting operating expenses, primarily in research and development. This financial discipline, coupled with a healthy cash balance of $280.7 million, has garnered strong analyst support, with a median 12-month target price pointing to a 75% upside. The company's prudent financial management is seen as a model for success in a challenging biotech funding environment.
2025-11-10 16:05:00
Zentalis Pharmaceuticals reported its third-quarter 2025 financial results, highlighting ongoing progress in its DENALI Phase 2 trial for azenosertib, a WEE1 inhibitor targeting Cyclin E1-positive platinum-resistant ovarian cancer. The company maintains a strong financial position with $280.7 million in cash, cash equivalents, and marketable securities, projected to fund operations into late 2027. Topline data from the DENALI Part 2 trial is anticipated by year-end 2026, with the potential to support accelerated FDA approval.
2025-11-10 05:10:17
Zentalis Pharmaceuticals Inc. (ZNTL) has announced its Q3 2025 financial results, reporting a net loss of $26.7 million, an improvement from a $40.2 million loss in Q3 2024. The company, focused on developing the WEE1 inhibitor azenosertib, reduced its operating expenses significantly, particularly in research and development. Zentalis maintains a strong cash position of $39.1 million and remains committed to advancing its clinical programs and strategic collaborations.
2025-11-10 05:10:17
Zentalis Pharmaceuticals (ZNTL) reported its Q3 2025 financial results, highlighting progress in its DENALI Phase 2 trial for azenosertib, with topline data expected by late 2026. The company maintains a strong financial position with $280.7 million in cash, providing operational runway into late 2027, and has reduced R&D expenses. Although TipRanks’ AI Analyst, Spark, rates ZNTL as Neutral due to financial hurdles, the potential of azenosertib for aggressive cancers offers strategic value despite high risk.
2025-11-08 05:10:17
Insiders at Zentalis Pharmaceuticals who invested US$252.8k over the last year have seen their investment decrease in value by US$37k due to a recent 12% stock price drop. Despite this, insiders bought more shares than they sold, indicating potential bullishness, although their overall ownership remains relatively low at 1.6%.
